首页 > 最新文献

Farmatsevtichnii zhurnal最新文献

英文 中文
Development of composition and evaluation of equivalence of diacerein hard gelatin capsules 二糖精硬明胶胶囊的组成及等效性评价
Pub Date : 2021-12-20 DOI: 10.32352/0367-3057.6.21.06
О. О. Салій, О. В. Лось, О. П. Баула, В. Ю. Турчина
Diacerein is a new generation of symptomatic slow-acting agent for the treatment of osteoarthritis, when taken orally, it exhibits moderate anti-inflammatory and analgesic activity, slows down the decay of cartilage tissue and relieves pain and swelling, but its physicochemical properties it is practically insoluble in water, due to which only 35‒56% the drug reaches systemic circulation. Therefore, the search for approaches to increase the dissolution rate of a practically insoluble API using the formulation, type of excipients, degree of solubility and kinetics of the substance release from hard gelatin capsules should provide guaranteed drug efficacy. The aim of the work is to develop the composition of the drug in the form of hard gelatin capsules based on diacerein, to experimentally study the solubility of diacerein, and to evaluate the composition by studying the kinetics of dissolution of the drug. Determination of the pH-dependent solubility of diacerein was carried out in the conditions: the volume of the dissolution medium is 250 ml; dissolution temperature 37.0 ± 0.5 ºС. The highest recommended single dose of 50 mg was investigated. The development of the composition of the drug Diacerein, capsules, 50 mg was carried out with the use of various types of excipients and their modifications to achieve the proper technological properties in terms of fluidity (flowability) and a short disintegration time of the capsules for the release of the active substance. Comparative studies of the kinetics of dissolution were carried out by the in vitro method, the test «Dissolution» was studied a «Paddle apparatus» with a rotation speed of 75 rpm, a dissolution medium with a pH value of 1.2, 4.5 and 6.8, in a volume of 900 ml at a temperature of 37 ± 0.5 ºС. The reference drug was used «Artrodarin®», capsules of 50 mg, manufactured by TRB PHARMA S. A.,vArgentina. It was found that diacerein is practically insoluble in a buffer solution with a pH of 1.2, has a relatively low solubility in a buffer solution with a pH of 4.5, while the solubility of diacerein increases with an increase in the pH of the medium to 6.8. The optimal composition of capsules with diacerein using the wet granulation technology has been developed. The obtained data for bulk density and Carr's index indicate satisfactory flowability of the encapsulating mass. Comparative studies of the dissolution kinetics of the investigational medicinal product and the original drug «Artrodarin®», capsules of 50 mg were carried out. According to the calculations, all the obtained values of the similarity factor are in the range from 50 to 100 and indicate the similarity in buffer media with pH 1.2, 4.5 and 6.8. The developed composition of the preparation is equivalent in dissolution kinetics to the original medicine.
地黄精是新一代治疗骨关节炎的对症缓释剂,口服时具有适度的抗炎镇痛作用,减缓软骨组织的衰变,减轻疼痛和肿胀,但其理化性质几乎不溶于水,因此只有35-56%的药物进入体循环。因此,寻找提高几乎不溶性原料药溶出率的方法,包括配方、辅料类型、溶解度和物质从硬明胶胶囊中释放的动力学,应该能保证药物疗效。本工作的目的是研制以二乙酰甲苷为基础的硬明胶胶囊形式的药物组成,实验研究二乙酰甲苷的溶解度,并通过研究药物的溶解动力学来评价其组成。在溶出介质体积为250 ml的条件下,测定二乙酰甲苷的ph依赖性溶解度;溶解温度37.0±0.5ºС。研究了最高推荐单次剂量50毫克。该药物的组成,胶囊,50mg的开发与使用各种类型的赋形剂和他们的修改,以实现适当的技术性能方面的流动性(流动性)和短崩解时间的胶囊释放的活性物质。通过体外方法进行溶解动力学的比较研究,“溶解”试验在转速为75 rpm的“桨式装置”上进行,溶解介质的pH值为1.2,4.5和6.8,体积为900 ml,温度为37±0.5ºС。对照药物为Artrodarin®,50 mg胶囊,由vArgentina TRB PHARMA s.a生产。结果表明,二淫精在pH为1.2的缓冲溶液中几乎不溶,在pH为4.5的缓冲溶液中溶解度较低,而随着介质pH的增加,二淫精的溶解度增加到6.8。研究了湿法制粒技术制备双糖精胶囊的最佳配方。得到的堆积密度和卡尔指数数据表明,包封体具有令人满意的流动性。对试验药品和原药Artrodarin®(50mg胶囊)的溶出动力学进行了比较研究。通过计算,得到的相似系数均在50 ~ 100之间,表示在pH为1.2、4.5和6.8的缓冲介质中的相似度。所研制的制剂组合物在溶出动力学上与原药物等效。
{"title":"Development of composition and evaluation of equivalence of diacerein hard gelatin capsules","authors":"О. О. Салій, О. В. Лось, О. П. Баула, В. Ю. Турчина","doi":"10.32352/0367-3057.6.21.06","DOIUrl":"https://doi.org/10.32352/0367-3057.6.21.06","url":null,"abstract":"Diacerein is a new generation of symptomatic slow-acting agent for the treatment of osteoarthritis, when taken orally, it exhibits moderate anti-inflammatory and analgesic activity, slows down the decay of cartilage tissue and relieves pain and swelling, but its physicochemical properties it is practically insoluble in water, due to which only 35‒56% the drug reaches systemic circulation. Therefore, the search for approaches to increase the dissolution rate of a practically insoluble API using the formulation, type of excipients, degree of solubility and kinetics of the substance release from hard gelatin capsules should provide guaranteed drug efficacy. \u0000The aim of the work is to develop the composition of the drug in the form of hard gelatin capsules based on diacerein, to experimentally study the solubility of diacerein, and to evaluate the composition by studying the kinetics of dissolution of the drug. \u0000Determination of the pH-dependent solubility of diacerein was carried out in the conditions: the volume of the dissolution medium is 250 ml; dissolution temperature 37.0 ± 0.5 ºС. The highest recommended single dose of 50 mg was investigated. The development of the composition of the drug Diacerein, capsules, 50 mg was carried out with the use of various types of excipients and their modifications to achieve the proper technological properties in terms of fluidity (flowability) and a short disintegration time of the capsules for the release of the active substance. Comparative studies of the kinetics of dissolution were carried out by the in vitro method, the test «Dissolution» was studied a «Paddle apparatus» with a rotation speed of 75 rpm, a dissolution medium with a pH value of 1.2, 4.5 and 6.8, in a volume of 900 ml at a temperature of 37 ± 0.5 ºС. The reference drug was used «Artrodarin®», capsules of 50 mg, manufactured by TRB PHARMA S. A.,vArgentina. \u0000It was found that diacerein is practically insoluble in a buffer solution with a pH of 1.2, has a relatively low solubility in a buffer solution with a pH of 4.5, while the solubility of diacerein increases with an increase in the pH of the medium to 6.8. The optimal composition of capsules with diacerein using the wet granulation technology has been developed. The obtained data for bulk density and Carr's index indicate satisfactory flowability of the encapsulating mass. Comparative studies of the dissolution kinetics of the investigational medicinal product and the original drug «Artrodarin®», capsules of 50 mg were carried out. According to the calculations, all the obtained values of the similarity factor are in the range from 50 to 100 and indicate the similarity in buffer media with pH 1.2, 4.5 and 6.8. The developed composition of the preparation is equivalent in dissolution kinetics to the original medicine.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44952183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicines manufactured in pharmacies: features of validation of analytical methods and tests (Prior to the introduction of the monograph section of the SPU) 药店生产的药品:分析方法和测试的验证特征(在引入SPU专著部分之前)
Pub Date : 2021-12-20 DOI: 10.32352/0367-3057.6.21.08
О. А. Євтіфєєва, В. А. Георгіянц
In most foreign countries, compounding medicines preparation are an important element of the pharmaceutical sector, the formulation of which is being distributed and developed taking into account the needs of today. Legal regulation of the circulation of these drugs is subject to the general requirements of the National Pharmacopoeia and the EuPh to SPhU but is carried out taking into account the characteristics of compounding medicines preparation: individual purpose, formulation, manufacture, quality control and implementation. In Ukraine, SPhU has monographs on various categories of compounding medicines preparation. But today there are some issues to ensure the quality control of compounding medicines preparation, which need to be consistent with the general requirements for medicines. The purpose of this work is to generalize the previously defined approaches and evaluate the results of their use in experimental studies on the development and validation of methods for quality control of compounding medicines preparation; substantiation and development of a fragment of the general monograph «Compounding medicines preparation» of SPhU. As a result of a critical analysis of the general requirements for validation of analysis methods and specifics of compounding medicines preparation, a standardized validation procedure was developed. When forming the tolerances of the content of individual ingredients in pharmaceutical dosage forms, the SPhU approach was chosen, that is the tolerances of the content at the level of ± 5%, ± 10%, ± 15% were chosen. Approbation of the standardized procedure for validation of methods for the quantitative determination of API in drugs manufactured in pharmacies was carried out on a significant number of names of about 50 compounding medicines preparation using spectrophotometric, photocolorimetric, refractometric and titrimetric methods of analysis. Studies have been conducted for different categories of drugs: concentrate solutions, semi-finished products, drugs made in stock, drugs made from finished drugs. The proposed standardized procedure for validation of analytical methods allows controlling of the quality of compounding medicines preparation in accordance with the requirements of the SPhU and avoids excessive costs. Based on the statistical analysis of experimental data, a draft part of the general monograph on compounding medicines preparation was formed: validation of analytical methods and tests.
在大多数外国,复合药物制剂是制药部门的一个重要组成部分,其配方正在考虑到今天的需要进行分发和开发。这些药物流通的法律监管受国家药典和欧洲药典对SPhU的一般要求的约束,但考虑到复方药物制剂的特点:个人用途、配方、制造、质量控制和实施。在乌克兰,SPhU有关于各种复合药物制剂的专著。但目前复方制剂的质量控制存在一些问题,需要符合药品的一般要求。这项工作的目的是概括以前定义的方法,并评估它们在开发和验证复方药物制剂质量控制方法的实验研究中的使用结果;巩固和发展SPhU的一般专著“复方药物制剂”的一部分。由于对分析方法验证的一般要求和复方药物制剂的具体要求进行了批判性分析,因此制定了标准化的验证程序。在形成药物剂型中单个成分含量的耐受性时,选择SPhU法,即选择含量在±5%、±10%、±15%水平下的耐受性。对使用分光光度法、光比色法、折射法和滴定法分析的约50种复方药物制剂的大量名称进行了标准化程序验证,批准了药店生产的药物中API的定量测定方法。对不同类别的药物进行了研究:浓缩溶液、半成品、库存药物、由成品药物制成的药物。建议的分析方法验证的标准化程序允许根据SPhU的要求控制复方药物制剂的质量,并避免过多的成本。在对实验数据进行统计分析的基础上,形成了复方制剂通用专论的一部分草案:分析方法和试验的验证。
{"title":"Medicines manufactured in pharmacies: features of validation of analytical methods and tests (Prior to the introduction of the monograph section of the SPU)","authors":"О. А. Євтіфєєва, В. А. Георгіянц","doi":"10.32352/0367-3057.6.21.08","DOIUrl":"https://doi.org/10.32352/0367-3057.6.21.08","url":null,"abstract":"In most foreign countries, compounding medicines preparation are an important element of the pharmaceutical sector, the formulation of which is being distributed and developed taking into account the needs of today. Legal regulation of the circulation of these drugs is subject to the general requirements of the National Pharmacopoeia and the EuPh to SPhU but is carried out taking into account the characteristics of compounding medicines preparation: individual purpose, formulation, manufacture, quality control and implementation. \u0000In Ukraine, SPhU has monographs on various categories of compounding medicines preparation. But today there are some issues to ensure the quality control of compounding medicines preparation, which need to be consistent with the general requirements for medicines. \u0000The purpose of this work is to generalize the previously defined approaches and evaluate the results of their use in experimental studies on the development and validation of methods for quality control of compounding medicines preparation; substantiation and development of a fragment of the general monograph «Compounding medicines preparation» of SPhU. \u0000As a result of a critical analysis of the general requirements for validation of analysis methods and specifics of compounding medicines preparation, a standardized validation procedure was developed. When forming the tolerances of the content of individual ingredients in pharmaceutical dosage forms, the SPhU approach was chosen, that is the tolerances of the content at the level of ± 5%, ± 10%, ± 15% were chosen. \u0000Approbation of the standardized procedure for validation of methods for the quantitative determination of API in drugs manufactured in pharmacies was carried out on a significant number of names of about 50 compounding medicines preparation using spectrophotometric, photocolorimetric, refractometric and titrimetric methods of analysis. Studies have been conducted for different categories of drugs: concentrate solutions, semi-finished products, drugs made in stock, drugs made from finished drugs. \u0000The proposed standardized procedure for validation of analytical methods allows controlling of the quality of compounding medicines preparation in accordance with the requirements of the SPhU and avoids excessive costs. \u0000Based on the statistical analysis of experimental data, a draft part of the general monograph on compounding medicines preparation was formed: validation of analytical methods and tests.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48070798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Analysis of the number of registered patients whis rare diseases in some regions of Ukraine 乌克兰一些地区罕见病登记患者数量分析
Pub Date : 2021-12-20 DOI: 10.32352/0367-3057.6.21.03
М. В. Подгайна, Н. А. Сліпцова, В. В. Тутук
Rare (orphan) diseases (RD) are a global priority for health systems. In Europe, including Ukraine, the disease is considered rare with a prevalence of 1 patient per 2,000 population. To date, by the orphanet data, 6,172 unique rare diseases have been discovered. An important issue today is the understanding and analysis of data on the prevalence of RD in Ukraine, which will effectively plan the need for therapy and predict its cost. Aim of the investigation was to analyze the available data on the of the registered cases of orphan diseases among children and adults in all Ukraine’s regions and determining the share of each disease in the overall structure in terms of age group of patients. The object of the in vestigation are data of the Department of Statistics of the Ministry of Health on the cases of rare diseases, that were registered in Ukraine as of January 2020 and Medical Genetics Center’s data. The study was conducted using informative methods of analysis (collection and data processing), systematization and generalization, mathematical and statistical calculations. According to the Сenter’s of Medical Statistics of the Ministry of Health data the total number of registered patients was 10786 patients, of whom children accounted for 54%. Among given diseases the largest proportion of patients had been registered with a diagnosis of «juvenile rheumatoid arthritis» – 2,291 patients, most of whom, almost 80%, are children. Among 18 rare diseases, 11%, were registered only among pediatric patients: Pump's disease, Fabri's disease. It has been established that Kyiv, Poltava, Dnipro, Ivano-Frankivsk and Kharkiv regions had been characterized by the highest total number of orphan patients. Regions with the lowestregistered number of orphan patients – are Luhansk, Lviv, Kherson, Sumyand Volyn. There was no information on registered RDs in Chernivtsi, Odesa, Zakarpattia regions and Kyiv city from the Center for Medical Statistics of the Ministry of Health, but it was indicated the cases of four RDs in Odessa region and Kyiv city by newborn screening program in 2020, that has shown problems in the collection, centralization and coordination of the statistic information of RDs and needs to be resolved in the future at the state and regional levels.
罕见(孤儿)病是全球卫生系统的一个优先事项。在欧洲,包括乌克兰,这种疾病被认为是罕见的,每2000人中只有1名患者。迄今为止,根据孤儿院的数据,已经发现了6172种独特的罕见疾病。今天的一个重要问题是了解和分析乌克兰RD患病率的数据,这将有效地规划治疗需求并预测其费用。调查的目的是分析乌克兰所有地区儿童和成人孤儿病登记病例的现有数据,并确定每一种疾病在总体结构中按患者年龄组所占的比例。调查的对象是截至2020年1月在乌克兰登记的卫生部统计司关于罕见病病例的数据和医学遗传学中心的数据。研究采用了信息性分析(收集和数据处理)、系统化和一般化、数学和统计计算等方法。根据卫生部医学统计网站Сenter的数据,登记患者总数为10786例,其中儿童占54%。在已登记的疾病中,诊断为"幼年类风湿性关节炎"的患者所占比例最大,有2,291名患者,其中大多数是儿童,几乎占80%。在18种罕见病中,11%仅在儿科患者中登记:泵病,法布里病。已经确定,基辅、波尔塔瓦、第聂伯罗、伊万诺-弗兰科夫斯克和哈尔科夫地区的孤儿病人总数最多。登记孤儿人数最少的地区是卢甘斯克、利沃夫、赫尔松、苏梅扬和沃林。卫生部医学统计中心没有Chernivtsi、Odesa、Zakarpattia地区和Kyiv市的注册rd信息,但通过2020年的新生儿筛查项目指出,敖德萨地区和Kyiv市的四个rd病例表明,rd统计信息的收集、集中和协调存在问题,未来需要在国家和地区层面解决。
{"title":"Analysis of the number of registered patients whis rare diseases in some regions of Ukraine","authors":"М. В. Подгайна, Н. А. Сліпцова, В. В. Тутук","doi":"10.32352/0367-3057.6.21.03","DOIUrl":"https://doi.org/10.32352/0367-3057.6.21.03","url":null,"abstract":"Rare (orphan) diseases (RD) are a global priority for health systems. In Europe, including Ukraine, the disease is considered rare with a prevalence of 1 patient per 2,000 population. To date, by the orphanet data, 6,172 unique rare diseases have been discovered. An important issue today is the understanding and analysis of data on the prevalence of RD in Ukraine, which will effectively plan the need for therapy and predict its cost. \u0000Aim of the investigation was to analyze the available data on the of the registered cases of orphan diseases among children and adults in all Ukraine’s regions and determining the share of each disease in the overall structure in terms of age group of patients. \u0000The object of the in vestigation are data of the Department of Statistics of the Ministry of Health on the cases of rare diseases, that were registered in Ukraine as of January 2020 and Medical Genetics Center’s data. The study was conducted using informative methods of analysis (collection and data processing), systematization and generalization, mathematical and statistical calculations. \u0000According to the Сenter’s of Medical Statistics of the Ministry of Health data the total number of registered patients was 10786 patients, of whom children accounted for 54%. Among given diseases the largest proportion of patients had been registered with a diagnosis of «juvenile rheumatoid arthritis» – 2,291 patients, most of whom, almost 80%, are children. Among 18 rare diseases, 11%, were registered only among pediatric patients: Pump's disease, Fabri's disease. It has been established that Kyiv, Poltava, Dnipro, Ivano-Frankivsk and Kharkiv regions had been characterized by the highest total number of orphan patients. Regions with the lowestregistered number of orphan patients – are Luhansk, Lviv, Kherson, Sumyand Volyn. There was no information on registered RDs in Chernivtsi, Odesa, Zakarpattia regions and Kyiv city from the Center for Medical Statistics of the Ministry of Health, but it was indicated the cases of four RDs in Odessa region and Kyiv city by newborn screening program in 2020, that has shown problems in the collection, centralization and coordination of the statistic information of RDs and needs to be resolved in the future at the state and regional levels.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48356082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of physicochemical characteristics of calcium hydroxyapatite «Kalident Powder 100» in the development of dental medicine 羟基磷灰石钙“钾化粉100”的理化特性研究在口腔医学开发中的应用
Pub Date : 2021-12-20 DOI: 10.32352/0367-3057.6.21.05
Ю. С. Маслій, К. В. Крива, І. В. Ковалевська, О. А. Рубан, О. О. Ляпунова
Despite the development of the dental industry, the prevalence of dental hypersensitivity does not decrease but increases at a progressive rate. Given the above, the subject of our research was the development of dental medicinal films with micronized calcium hydroxyapatite under the trade name «Kalident Powder 100» (Kalichem, Italy) for the treatment of dental hyperesthesia and caries prevention. To establish the optimal method of calcium hydroxyapatite introduction into the dental film, it was necessary to study the influence of different dispersion mediums on the physicochemical characteristics of the substance under study. Purified water, ethyl alcohol 96%, polysorbate 80, glycerol, polyethylene oxide-400, propylene glycol, sunflower oil, vaseline oil were used as dispersion medium in the studies. Research of physico-chemical characteristics was performed both for the substance «Kalident Powder 100» separately and for its mixtures with the studied liquids and their combinations (in a ratio of 1:1). The following physico-chemical characteristics have been determined: disperse and diffraction analysis of particle size distribution, morphological description, linear dimensions, shape factor, volume coefficient, Martin and Ferret diameters, wettability. The results of crystallographic and disperse analysis have revealed the polydispersity of the substance «Kalident Powder 100» and its high ability to agglomerate, which may adversely affect the homogeneity of its distribution in the dental medicinal product. A study of the effect of different dispersion medium on the physicochemical characteristics of calcium hydroxyapatite has shown a positive effect of hydrophilic liquids on the wettability of powder particles, changes in their shape, size, and distribution in the studied samples. It has been established that the combination of the substance «Kalident Powder 100» with combined solvent systems containing purified water, polysorbate 80, glycerol, and PEO-400, allows achieving optimal shape and particle size of calcium hydroxyapatite with their uniform distribution throughout the liquid, which is also confirmed by the results of laser diffraction. The obtained results will be used in further research on the development of dental medicinal film.
尽管牙科行业得到了发展,但牙齿过敏的患病率并没有下降,而是以渐进的速度增加。鉴于上述情况,我们的研究主题是开发商品名为“Kalident Powder 100”(Kalichem,意大利)的具有微粉化羟基磷灰石钙的牙科药用薄膜,用于治疗牙齿过敏和预防龋齿。为了确定将羟基磷灰石钙引入牙膜的最佳方法,有必要研究不同分散介质对所研究物质物理化学特性的影响。以纯水、乙醇96%、聚山梨醇酯80、甘油、聚环氧乙烷-400、丙二醇、葵花籽油、凡士林油为分散介质。分别对“Kalident Powder 100”物质及其与研究液体的混合物及其组合(比例为1:1)进行了物理化学特性研究。已经确定了以下物理化学特性:粒度分布的分散和衍射分析、形态描述、线性尺寸、形状因子、体积系数、Martin和Ferret直径、润湿性。结晶和分散分析结果表明,“Kalident Powder 100”物质具有多分散性及其高团聚能力,这可能会对其在牙科药品中的分布均匀性产生不利影响。研究了不同分散介质对羟基磷灰石钙物理化学特性的影响,结果表明亲水性液体对粉末颗粒的润湿性、形状、尺寸和分布的变化有积极影响。已经证实,将“Kalident Powder 100”物质与含有纯化水、聚山梨醇酯80、甘油和PEO-400的组合溶剂系统相结合,可以实现羟基磷灰石钙的最佳形状和颗粒尺寸,其在整个液体中的均匀分布,这也得到了激光衍射结果的证实。所得结果将用于进一步研究口腔药用薄膜的开发。
{"title":"Study of physicochemical characteristics of calcium hydroxyapatite «Kalident Powder 100» in the development of dental medicine","authors":"Ю. С. Маслій, К. В. Крива, І. В. Ковалевська, О. А. Рубан, О. О. Ляпунова","doi":"10.32352/0367-3057.6.21.05","DOIUrl":"https://doi.org/10.32352/0367-3057.6.21.05","url":null,"abstract":"Despite the development of the dental industry, the prevalence of dental hypersensitivity does not decrease but increases at a progressive rate. Given the above, the subject of our research was the development of dental medicinal films with micronized calcium hydroxyapatite under the trade name «Kalident Powder 100» (Kalichem, Italy) for the treatment of dental hyperesthesia and caries prevention. To establish the optimal method of calcium hydroxyapatite introduction into the dental film, it was necessary to study the influence of different dispersion mediums on the physicochemical characteristics of the substance under study. \u0000Purified water, ethyl alcohol 96%, polysorbate 80, glycerol, polyethylene oxide-400, propylene glycol, sunflower oil, vaseline oil were used as dispersion medium in the studies. Research of physico-chemical characteristics was performed both for the substance «Kalident Powder 100» separately and for its mixtures with the studied liquids and their combinations (in a ratio of 1:1). The following physico-chemical characteristics have been determined: disperse and diffraction analysis of particle size distribution, morphological description, linear dimensions, shape factor, volume coefficient, Martin and Ferret diameters, wettability. \u0000The results of crystallographic and disperse analysis have revealed the polydispersity of the substance «Kalident Powder 100» and its high ability to agglomerate, which may adversely affect the homogeneity of its distribution in the dental medicinal product. A study of the effect of different dispersion medium on the physicochemical characteristics of calcium hydroxyapatite has shown a positive effect of hydrophilic liquids on the wettability of powder particles, changes in their shape, size, and distribution in the studied samples. It has been established that the combination of the substance «Kalident Powder 100» with combined solvent systems containing purified water, polysorbate 80, glycerol, and PEO-400, allows achieving optimal shape and particle size of calcium hydroxyapatite with their uniform distribution throughout the liquid, which is also confirmed by the results of laser diffraction. The obtained results will be used in further research on the development of dental medicinal film.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48847900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of extemporal production trends in pharmacies for children 儿童药房临时生产趋势分析
Pub Date : 2021-12-20 DOI: 10.32352/0367-3057.6.21.02
О. М. Заліська, Ю. В. Качерай, З. О. Заболотня, О. М. Семенов
Medicines for children are insufficiently represented in pediatric dosages and appropriate dosage forms in the pharmaceutical market of Ukraine. Pediatricians are forced to prescribe children's medicines in dosages that are not available in the State Register of Medicines of Ukraine. Extemporaneously compounded medicines (ECM) are useful when a required dose or dose form is unavailable commercially, or is needed for individualised dosing. The aim of the study was to analysis a real data of the list of  medicines which are produced in hospital and public pharmacies of Lviv region during 2020–2021. Methods. Content analysis of extemporal prescriptions for children, depending on the composition of the active pharmaceutical ingredient, dose and dosage form, comparative cost analysis of ECM and industrial medicines. In the hospital doctors prescribe ECМ in liquid forms (75%) – solutions for injection and in solid forms (25%) – dosed simple powders – 19%, dosed complex powders – 6%. It was determined the structure of  ECM, which are produced in 6 studied pharmacies in 2020–2021. There are soft ECM 61.6% in dosage forms: ointments, creams, paste; liquid ECM are 28.3% in mixtures, solutions, mumbles; solid ECM are 8.3% in mono, combine powders, suppositories and 1.8% – other ECM: powders and nail polishs. There were highlighted unique recipes of ECM which analogues were not present in industrial dosage forms. We conducted analysis of the cost of children’s ECM in these pharmacies. It was determined that ECM cost were 40.5–305.6 UAH depending on the dosage form. The comparative analysis showed that ECM are in 2.2–4.9 times more cheaper for children compare with similar active ingredients in industrial medicines. ECMs are much more compliant for treatment in children and babies, they provide higher effect, safety, reduce dosing errors, especially at the inpatient stage, and continuation of therapy on an outpatient basis and  more cost-effective for individual needs. The use of ECMs allows parents to properly dose them for children, to avoid errors in dosing, improper administration, which is extremely important to ensure the rational use of medicines in pediatric practice.
在乌克兰药品市场上,儿童用药在儿科剂量和适当剂型方面的代表性不足。儿科医生被迫以乌克兰国家药品登记册上没有的剂量开儿童药品。当商业上无法获得所需剂量或剂型,或需要个体化给药时,临时复方药物(ECM)是有用的。该研究的目的是分析2020-2021年期间利沃夫地区医院和公共药房生产的药品清单的真实数据。方法。儿童临时处方的含量分析,根据活性药物成分的组成,剂量和剂型,ECM和工业药物的比较成本分析。在医院里,医生开出ECМ的处方为液体形式(75%)——注射用溶液和固体形式(25%)——简单粉末剂量占19%,复合粉末剂量占6%。确定了6家被研究药店2020-2021年生产的ECM的结构。软性ECM占剂型的61.6%:软膏、面霜、膏;液体ECM在混合物、溶液、液体中占28.3%;固体ECM是8.3%的单一,组合粉末,栓剂和1.8%的其他ECM:粉末和指甲油。强调了ECM的独特配方,其类似物在工业剂型中不存在。我们对这些药店的儿童ECM费用进行了分析。根据剂型的不同,ECM的成本为40.5-305.6 UAH。对比分析表明,与工业药品中类似活性成分相比,ECM对儿童的价格便宜2.2-4.9倍。ecm更适合儿童和婴儿的治疗,它们提供更高的效果,安全性,减少剂量错误,特别是在住院阶段,并且在门诊基础上继续治疗,并且对个人需求更具成本效益。ecm的使用使家长能够为儿童正确给药,避免给药错误、给药不当,这对确保儿科实践中药物的合理使用极为重要。
{"title":"Analysis of extemporal production trends in pharmacies for children","authors":"О. М. Заліська, Ю. В. Качерай, З. О. Заболотня, О. М. Семенов","doi":"10.32352/0367-3057.6.21.02","DOIUrl":"https://doi.org/10.32352/0367-3057.6.21.02","url":null,"abstract":"Medicines for children are insufficiently represented in pediatric dosages and appropriate dosage forms in the pharmaceutical market of Ukraine. Pediatricians are forced to prescribe children's medicines in dosages that are not available in the State Register of Medicines of Ukraine. Extemporaneously compounded medicines (ECM) are useful when a required dose or dose form is unavailable commercially, or is needed for individualised dosing. \u0000The aim of the study was to analysis a real data of the list of  medicines which are produced in hospital and public pharmacies of Lviv region during 2020–2021. \u0000Methods. Content analysis of extemporal prescriptions for children, depending on the composition of the active pharmaceutical ingredient, dose and dosage form, comparative cost analysis of ECM and industrial medicines. \u0000In the hospital doctors prescribe ECМ in liquid forms (75%) – solutions for injection and in solid forms (25%) – dosed simple powders – 19%, dosed complex powders – 6%. It was determined the structure of  ECM, which are produced in 6 studied pharmacies in 2020–2021. There are soft ECM 61.6% in dosage forms: ointments, creams, paste; liquid ECM are 28.3% in mixtures, solutions, mumbles; solid ECM are 8.3% in mono, combine powders, suppositories and 1.8% – other ECM: powders and nail polishs. There were highlighted unique recipes of ECM which analogues were not present in industrial dosage forms. \u0000We conducted analysis of the cost of children’s ECM in these pharmacies. It was determined that ECM cost were 40.5–305.6 UAH depending on the dosage form. The comparative analysis showed that ECM are in 2.2–4.9 times more cheaper for children compare with similar active ingredients in industrial medicines. \u0000ECMs are much more compliant for treatment in children and babies, they provide higher effect, safety, reduce dosing errors, especially at the inpatient stage, and continuation of therapy on an outpatient basis and  more cost-effective for individual needs. The use of ECMs allows parents to properly dose them for children, to avoid errors in dosing, improper administration, which is extremely important to ensure the rational use of medicines in pediatric practice.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47506407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Study of the advantages and risks of electronic retail trade in medicines 药品电子零售贸易的优势与风险研究
Pub Date : 2021-12-20 DOI: 10.32352/0367-3057.6.21.01
О. О. Комаріда, С. Г. Убогов, Н. В. Суртаєва, В. І. Тодорова, Л. О. Федорова
One of the most important issues of interest to scientists and practitioners of pharmacy is medicines quality assurance at all stages of their life cycle. From 2021 in Ukraine, the retail trade of medicines via the Internet was allowed. The system of electronic (distance) retail trade (ERT) has its obvious advantages for consumers of pharmaceutical services, but also its potential risks for the medicines quality being sold. The aim of the study is analysis of legislative innovations on ERT in medicines, determination of advantages and possible problems of ERT in medicines, identification of potential risks to the medicines quality during ERT and determination of organizational and practical measures to prevent and minimize them. The research materials were scientific publications, legislative and regulatory acts of Ukraine and the EU, public information of public authorities and pharmaceutical enterprises, data from own observations. The following methods were used in the work: system and content analysis, generalization, systematization, structural-logical, visual-graphic. The analysis of sources of scientific and professional literature showed that domestic and foreign scientists have studied the legal, socio-economic and marketing aspects of ERT in medicines. We studied this issue from the standpoint of quality assurance and risk management for the medicines quality. The paper provides a system and content analysis of legislative innovations on ERT in medicines, summarizes and systematizes the general and special requirements for the procedure for ERT in medicines, identifies the advantages and possible problems of ERT in medicines. The structural and logical scheme of the ERT in medicines process is developed. It is proposed to use this scheme as a basis for the regulation and documentation of the ERT in medicines process by developing appropriate regulatory and instructional documents (regulations or techniques for performing the process, standard operating procedures, work instructions, etc.). According to the research results, the potential risks for the medicines quality in the conditions of ERT are identified and the complex of organizational and practical measures for their prevention and minimization is determined. It is proposed to implement this complex in the overall risk management process for the medicines quality and pharmaceutical services, which should be an integral part of the quality management system of the pharmaceutical enterprise that performs ERT in medicines. These measures should be taken into account when developing standard operating procedures for different stages of ERT in medicines and documentation on risk management for the medicines quality (passports of risk profiles, risk register, risk management plan, etc.).
科学家和药学从业者感兴趣的最重要问题之一是药物生命周期各个阶段的质量保证。从2021年起,乌克兰允许通过互联网进行药品零售贸易。电子(远程)零售贸易(ERT)系统对药品服务的消费者有着明显的优势,但也对所销售的药品质量有潜在的风险。本研究的目的是分析药品ERT的立法创新,确定药品ERT在药品ERT中的优势和可能存在的问题,识别ERT过程中对药品质量的潜在风险,并确定预防和最大限度地减少这些风险的组织和实际措施。研究材料包括科学出版物、乌克兰和欧盟的立法和监管法案、公共当局和制药企业的公共信息、自己观察到的数据。工作中采用了以下方法:系统和内容分析法、概括法、系统化法、结构逻辑法、直观图解法。对科学和专业文献来源的分析表明,国内外科学家对药品ERT的法律、社会经济和营销方面进行了研究。我们从药品质量保证和风险管理的角度来研究这个问题。本文对药品ERT的立法创新进行了系统和内容分析,总结和系统化了药品ERT程序的一般和特殊要求,指出了药品ERT的优势和可能存在的问题。提出了药品过程ERT的结构和逻辑方案。建议通过制定适当的监管和指导文件(执行该过程的法规或技术、标准操作程序、工作说明书等),将该方案作为药品过程中ERT监管和文件编制的基础。根据研究结果,确定了ERT条件下药品质量的潜在风险,并确定了预防和最小化这些风险的组织和实际措施的复杂性。建议在药品质量和药品服务的整体风险管理过程中实施这一复杂性,这应该是在药品中执行ERT的制药企业质量管理体系的组成部分。在制定药品ERT不同阶段的标准操作程序和药品质量风险管理文件(风险简介护照、风险登记册、风险管理计划等)时,应考虑到这些措施。
{"title":"Study of the advantages and risks of electronic retail trade in medicines","authors":"О. О. Комаріда, С. Г. Убогов, Н. В. Суртаєва, В. І. Тодорова, Л. О. Федорова","doi":"10.32352/0367-3057.6.21.01","DOIUrl":"https://doi.org/10.32352/0367-3057.6.21.01","url":null,"abstract":"One of the most important issues of interest to scientists and practitioners of pharmacy is medicines quality assurance at all stages of their life cycle. From 2021 in Ukraine, the retail trade of medicines via the Internet was allowed. The system of electronic (distance) retail trade (ERT) has its obvious advantages for consumers of pharmaceutical services, but also its potential risks for the medicines quality being sold. \u0000The aim of the study is analysis of legislative innovations on ERT in medicines, determination of advantages and possible problems of ERT in medicines, identification of potential risks to the medicines quality during ERT and determination of organizational and practical measures to prevent and minimize them. \u0000The research materials were scientific publications, legislative and regulatory acts of Ukraine and the EU, public information of public authorities and pharmaceutical enterprises, data from own observations. The following methods were used in the work: system and content analysis, generalization, systematization, structural-logical, visual-graphic. \u0000The analysis of sources of scientific and professional literature showed that domestic and foreign scientists have studied the legal, socio-economic and marketing aspects of ERT in medicines. We studied this issue from the standpoint of quality assurance and risk management for the medicines quality. \u0000The paper provides a system and content analysis of legislative innovations on ERT in medicines, summarizes and systematizes the general and special requirements for the procedure for ERT in medicines, identifies the advantages and possible problems of ERT in medicines. The structural and logical scheme of the ERT in medicines process is developed. It is proposed to use this scheme as a basis for the regulation and documentation of the ERT in medicines process by developing appropriate regulatory and instructional documents (regulations or techniques for performing the process, standard operating procedures, work instructions, etc.). \u0000According to the research results, the potential risks for the medicines quality in the conditions of ERT are identified and the complex of organizational and practical measures for their prevention and minimization is determined. It is proposed to implement this complex in the overall risk management process for the medicines quality and pharmaceutical services, which should be an integral part of the quality management system of the pharmaceutical enterprise that performs ERT in medicines. These measures should be taken into account when developing standard operating procedures for different stages of ERT in medicines and documentation on risk management for the medicines quality (passports of risk profiles, risk register, risk management plan, etc.).","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45957428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost analysis of botulinum therapy of spastic forms of cerebral palsy in Ukraine 乌克兰痉挛型脑瘫的肉毒杆菌治疗成本分析
Pub Date : 2021-12-20 DOI: 10.32352/0367-3057.6.21.04
С. О. Соловйов, О. В. Назар, М. В. Лелека
Cerebral palsy (CP) represents a group of disorders of the mechanisms of movement and body position, causing limitations of activity, which are caused by non-progressive damage to the developing brain, fetus or child. About 80% of cases are spastic forms of cerebral palsy. Along with motor rehabilitation, the use of botulinum toxin type A (BoNT-A) is considered one of the main methods of treatment of choice for focal spastic and dystonic syndromes, regardless of their etiology. At present, there are no studies in Ukraine on the analysis of the costs of using drugs based on BoNT-A, taking into account the recommended dose and frequency of administration. The aim of the work. Carrying out an analysis of minimizing the cost of botulinum therapy for spastic forms of cerebral palsy in patients aged two years and older. The annual dosage and frequency of administration of abobotulotoxin and onabotolutoxin for the treatment of dynamic equinus deformity of the foot caused by focal spasticity due to cerebral palsy in children over two years of age were obtained from the instructions for use. The cost of abobotulotoxin and onabotolutoxin was obtained from the Register of Wholesale Prices of the Ministry of Health of Ukraine. Cost analysis for a model cohort of children in different weight categories showed that abobotulotoxin 500 U will be the least expensive treatment technology in the weight category of 21–33 kg at a dosage of 15 U/kg in the treatment of diplegia. Abobotulotoxin 300 U is most rationally used in weight categories 10–20 kg and 34–40 kg with a dosage of 15 U/kg in the treatment of hemiplegia and in the weight category 17–20 kg with a dosage of 30 U/kg in the treatment of diplegia. Weight categories were identified in which the costs of using abobotulotoxin 300 U and abobotulotoxin 500 U were equal to and less than the costs of onabotolutoxin treatment. The study was the first to analyze the cost of botulinum therapy, which identified the benefits of abobotulotoxin in the symptomatic treatment of hemiplegia and diplegia in cerebral palsy in the focus of different weight groups of children. Possible variability in the dosage and frequency of administration of onabotolutoxin per year indicates the relevance of collecting additional information on the application in real clinical practice and further pharmacoeconomic studies.
脑瘫(CP)是一组运动和体位机制紊乱,导致活动受限,这是由发育中的大脑、胎儿或儿童的非进行性损伤引起的。大约80%的病例是痉挛型脑瘫。与运动康复一样,使用A型肉毒杆菌毒素(BoNT-A)被认为是治疗局灶性痉挛和肌张力障碍综合征的主要方法之一,无论其病因如何。目前,乌克兰没有对基于BoNT-A的药物使用成本进行分析的研究,考虑到推荐的剂量和给药频率。这项工作的目的。对两岁及以上痉挛型脑瘫患者进行肉毒杆菌毒素治疗成本最小化的分析。abobotulotoxin和onabotolutoxin用于治疗两岁以上儿童脑瘫引起的局灶性痉挛引起的足部动态马畸形的年剂量和给药频率从使用说明书中获得。abobotulotoxin和onabotolutoxin的成本从乌克兰卫生部批发价格登记处获得。对不同体重类别儿童模型队列的成本分析表明,在21-33公斤体重类别中,abobotulotoxin 500 U将是治疗双瘫的最便宜的治疗技术,剂量为15 U/kg。Abobotulotoxin 300 U最合理地用于10–20 kg和34–40 kg的体重类别,剂量为15 U/kg,用于治疗偏瘫;17–20 kg的体重类型,剂量为30 U/kg,可用于治疗双瘫。确定了使用abobotulotoxin 300U和abobotuletoxin 500U的成本等于或小于onabotolutoxin治疗成本的重量类别。该研究首次分析了肉毒杆菌毒素治疗的成本,确定了abobotulotoxin在不同体重组儿童脑瘫偏瘫和双瘫症状治疗中的益处。onabotolutoxin每年给药的剂量和频率可能存在差异,这表明收集有关在实际临床实践和进一步药物经济学研究中应用的额外信息具有相关性。
{"title":"Cost analysis of botulinum therapy of spastic forms of cerebral palsy in Ukraine","authors":"С. О. Соловйов, О. В. Назар, М. В. Лелека","doi":"10.32352/0367-3057.6.21.04","DOIUrl":"https://doi.org/10.32352/0367-3057.6.21.04","url":null,"abstract":"Cerebral palsy (CP) represents a group of disorders of the mechanisms of movement and body position, causing limitations of activity, which are caused by non-progressive damage to the developing brain, fetus or child. About 80% of cases are spastic forms of cerebral palsy. Along with motor rehabilitation, the use of botulinum toxin type A (BoNT-A) is considered one of the main methods of treatment of choice for focal spastic and dystonic syndromes, regardless of their etiology. At present, there are no studies in Ukraine on the analysis of the costs of using drugs based on BoNT-A, taking into account the recommended dose and frequency of administration. \u0000The aim of the work. Carrying out an analysis of minimizing the cost of botulinum therapy for spastic forms of cerebral palsy in patients aged two years and older. \u0000The annual dosage and frequency of administration of abobotulotoxin and onabotolutoxin for the treatment of dynamic equinus deformity of the foot caused by focal spasticity due to cerebral palsy in children over two years of age were obtained from the instructions for use. The cost of abobotulotoxin and onabotolutoxin was obtained from the Register of Wholesale Prices of the Ministry of Health of Ukraine. \u0000Cost analysis for a model cohort of children in different weight categories showed that abobotulotoxin 500 U will be the least expensive treatment technology in the weight category of 21–33 kg at a dosage of 15 U/kg in the treatment of diplegia. Abobotulotoxin 300 U is most rationally used in weight categories 10–20 kg and 34–40 kg with a dosage of 15 U/kg in the treatment of hemiplegia and in the weight category 17–20 kg with a dosage of 30 U/kg in the treatment of diplegia. Weight categories were identified in which the costs of using abobotulotoxin 300 U and abobotulotoxin 500 U were equal to and less than the costs of onabotolutoxin treatment. \u0000The study was the first to analyze the cost of botulinum therapy, which identified the benefits of abobotulotoxin in the symptomatic treatment of hemiplegia and diplegia in cerebral palsy in the focus of different weight groups of children. Possible variability in the dosage and frequency of administration of onabotolutoxin per year indicates the relevance of collecting additional information on the application in real clinical practice and further pharmacoeconomic studies.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49215411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research on the selection of a preservative for a soft dosage form with a water-soluble protein-polysaccharide complex of the fungus pleurotus ostreatus 白侧耳水溶性蛋白多糖复合物软剂型防腐剂的选择研究
Pub Date : 2021-12-20 DOI: 10.32352/0367-3057.6.21.07
О. А. Колпакова, Н. В. Кучеренко
One of the important aspects in the development of new drugs is their standardization and comprehensive assessment of quality indicators, which guarantees safety and stability throughout the life cycle of the drug. Soft drugs for external use with components of natural origin usually require the introduction of preservatives to ensure microbiological stability. Therefore, research on the selection of preservative is a necessary phase in pharmaceutical composition preparation. Purpose – foundation of the type choice and concentration of an effective preservative (or their combination) for the introduction into the composition of the ointment of anti-scarring activity with a water-soluble protein-polysaccharide complex of the fungus Pleurotus ostreatus. The object of the study was an original ointment composition based on an emulsion, the active component of which is a water-soluble protein-polysaccharide complex of the fungus Pleurotus ostreatus. To increase microbiological stability, preservatives were added to the samples, which are most common in soft dosage forms (nipagin:nipazol, triclosan, bronopol and benzoic acid). Determination of the sensitivity of ointment samples to microorganisms was performed by the method of diffusion into agar («well method»), as a microbiological model used a common set of test strains of reference cultures of gram-positive and gram-negative bacteria and fungi. The study found that sample 7 had demonstrated high antimicrobial properties, where the diameters of the growth retardation zones were 34–35 mm to Staphylococcus aureus ATCC 25923, Basillus subtilis ATCC 6633, 29–31 mm for Escherichia coli ATCC 25922, Proteus vulgaris ATCC 4636 and Pseudomonas aeruginosa ATCC 27853. Growth retardation zones were 27–28 mm to fungi Candida albicans ATCC 653/885. Bronopol was introduced into the sample, this preservative should provide the necessary microbiological purity and stability of the prepared ointment. Studies show that soft dosage forms with substances of natural origin require the administration of antimicrobial agents. It has been experimentally proven that 0.2% bronopol provides effective microbiological stability of the soft dosage form with anti-scarring activity of water-soluble protein-polysaccharide complex of the fungus Pleurotus ostreatus.
新药开发的一个重要方面是其质量指标的标准化和全面评估,这保证了药物整个生命周期的安全性和稳定性。含有天然成分的外用软性药物通常需要引入防腐剂,以确保微生物稳定性。因此,研究防腐剂的选择是药物制剂中一个必要的阶段。目的——有效防腐剂(或其组合)的类型选择和浓度的基础,用于将具有抗瘢痕活性的软膏与真菌平菇的水溶性蛋白质-多糖复合物引入组合物中。研究对象是一种基于乳液的原始软膏组合物,其活性成分是真菌平菇的水溶性蛋白质-多糖复合物。为了提高微生物稳定性,在样品中添加了防腐剂,这些防腐剂最常见于软剂型(尼泊金:尼泊唑、三氯生、溴苯酚和苯甲酸)。软膏样品对微生物的敏感性通过扩散到琼脂中的方法(“井法”)进行测定,因为微生物模型使用了革兰氏阳性和革兰氏阴性细菌和真菌参考培养物的一组常见测试菌株。研究发现,样品7具有较高的抗菌性能,其中生长迟缓区的直径对金黄色葡萄球菌ATCC 25923为34–35 mm,对枯草芽孢杆菌ATCC 6633为29–31 mm,对大肠杆菌ATCC 25922、普通变形杆菌ATCC 4636和绿脓杆菌ATCC 27853为29–31mm。真菌白色念珠菌ATCC 653/885的生长迟缓区为27-28 mm。Bronopol被引入样品中,这种防腐剂应提供所制备的软膏所需的微生物纯度和稳定性。研究表明,含有天然来源物质的软剂型需要使用抗菌剂。实验证明,0.2%溴氰醇具有有效的软剂型微生物稳定性,并具有真菌平菇水溶性蛋白质-多糖复合物的抗瘢痕活性。
{"title":"Research on the selection of a preservative for a soft dosage form with a water-soluble protein-polysaccharide complex of the fungus pleurotus ostreatus","authors":"О. А. Колпакова, Н. В. Кучеренко","doi":"10.32352/0367-3057.6.21.07","DOIUrl":"https://doi.org/10.32352/0367-3057.6.21.07","url":null,"abstract":"One of the important aspects in the development of new drugs is their standardization and comprehensive assessment of quality indicators, which guarantees safety and stability throughout the life cycle of the drug. \u0000Soft drugs for external use with components of natural origin usually require the introduction of preservatives to ensure microbiological stability. Therefore, research on the selection of preservative is a necessary phase in pharmaceutical composition preparation. \u0000Purpose – foundation of the type choice and concentration of an effective preservative (or their combination) for the introduction into the composition of the ointment of anti-scarring activity with a water-soluble protein-polysaccharide complex of the fungus Pleurotus ostreatus. \u0000The object of the study was an original ointment composition based on an emulsion, the active component of which is a water-soluble protein-polysaccharide complex of the fungus Pleurotus ostreatus. To increase microbiological stability, preservatives were added to the samples, which are most common in soft dosage forms (nipagin:nipazol, triclosan, bronopol and benzoic acid). Determination of the sensitivity of ointment samples to microorganisms was performed by the method of diffusion into agar («well method»), as a microbiological model used a common set of test strains of reference cultures of gram-positive and gram-negative bacteria and fungi. \u0000The study found that sample 7 had demonstrated high antimicrobial properties, where the diameters of the growth retardation zones were 34–35 mm to Staphylococcus aureus ATCC 25923, Basillus subtilis ATCC 6633, 29–31 mm for Escherichia coli ATCC 25922, Proteus vulgaris ATCC 4636 and Pseudomonas aeruginosa ATCC 27853. Growth retardation zones were 27–28 mm to fungi Candida albicans ATCC 653/885. Bronopol was introduced into the sample, this preservative should provide the necessary microbiological purity and stability of the prepared ointment. \u0000Studies show that soft dosage forms with substances of natural origin require the administration of antimicrobial agents. It has been experimentally proven that 0.2% bronopol provides effective microbiological stability of the soft dosage form with anti-scarring activity of water-soluble protein-polysaccharide complex of the fungus Pleurotus ostreatus.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48502853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of different doses of octenidine hexafluorosilicate on the development of dental caries in rats 不同剂量六氟硅酸辛替尼对大鼠龋发育的影响
Pub Date : 2021-12-20 DOI: 10.32352/0367-3057.6.21.10
В. Ю. Анісімов, І. Ю. Борисюк, В. О. Гельмбольдт
At present, ammonium hexafluorosilicate and hexafluorosilicates of organic amonium cations are actively studied as potential anticaries agents, which demonstrate certain advantages over traditional compounds of fluorine. Previously, it was shown that hexafluorosilicates with bactericidal cations of chlorhexidine, polyhexamethyleneguanidine and cetylpyridinium effectively reduce the number and depth of carious lesions of teeth in rats and at the same time significantly improve the biochemical parameters of the pulp of the teeth. The aim of the work – to study the effect of different doses of octenidine hexafluorosilicate (OHFS) on the incidence of dental caries in rats fed a cariogenic diet (CD). OHFC preparations were applied to the teeth and gums of rats in the composition of phytogels based on Na-salt of carboxymethylcellulose. In the incisor pulp, the activity of alkaline (ALP) and acidic (ACP) phosphatases, elastase, lysozyme was determined, and the mineralizing index (MI) was calculated. The number and depth of dental caries lesions were calculated and caries prophylactic efficacy (CPE) was calculated. The activity of elastase, catalase, lysozyme and urease was determined in the gums, and the degree of atrophy of the alveolar process was determined. Determination of dental caries lesions shows that CD does not increase the number of carious lesions, and after the application of gels with OHFS, their number significantly decreases. The most effective was the concentration of the OHFS gel, equal to 2 mg/ml, although the concentration of the OHFS gel 1 mg/ml showed a decrease by 33.3%. The calculated CPE is 33.3% for a gel with 1 mg/ml OHFS, 36.4% for a gel with 2 mg/ml and 24.2% for a gel with 4 mg/ml. It has been shown that in rats receiving CD, the ALP activity significantly decreases and the ACP activity significantly increases, which gives a significant decrease in MI from 43.9 to 28.9. Application of gels with OHFS returns the activity of both phosphatases to the control level and almost completely normalizes MI, and the concentration of OHFS gel of 2 mg/ml turned out to be the most effective. Application of gels with 1 mg/ml and 2 mg/ml OHFS reduced elastase activity by 6% and 12%, respectively, whereas application of a gel with 4 mg/ml OHFS did not result in a decrease in elastase activity. From the results of determining the degree of dysbiosis in the blood serum of rats, it can be seen that CD causes the development of generalized dysbiosis. Application of gels with OHFS significantly reduce the degree of dysbiosis, especially gels with OHFS concentrations of 1 and 2 mg/ml. Oral application of gels containing OHFS reduces the incidence of caries on the teeth, increases the mineralizing activity of the pulp and reduces the degree of generalized dysbiosis. The most effective concentration of the OHFS gel is 2 mg/ml, which corresponds to a dose of 2.2 mg/kg.
目前,有机铵离子的六氟硅酸铵和六氟硅酸铵作为潜在的抗菌剂被积极研究,它们比传统的氟化合物具有一定的优势。先前的研究表明,含氯己定、聚己基胍和十六烷基吡啶杀菌阳离子的六氟硅酸盐能有效减少大鼠牙齿龋齿的数量和深度,同时显著改善牙髓的生化参数。本研究旨在探讨不同剂量的六氟硅酸辛替尼(OHFS)对致龋饮食(CD)大鼠龋齿发生率的影响。以羧甲基纤维素钠盐为基础制备植物凝胶,应用于大鼠牙齿和牙龈。测定切牙髓内碱性磷酸酶(ALP)和酸性磷酸酶(ACP)、弹性酶、溶菌酶活性,计算矿化指数(MI)。计算龋齿的数量和深度,计算龋齿预防效果(CPE)。测定牙龈中弹性酶、过氧化氢酶、溶菌酶和脲酶的活性,测定肺泡突的萎缩程度。对龋齿病变的测定表明,CD不增加龋齿病变的数量,使用OHFS凝胶后,龋齿病变的数量明显减少。当OHFS凝胶浓度为2 mg/ml时效果最好,但当OHFS凝胶浓度为1 mg/ml时效果下降33.3%。OHFS浓度为1 mg/ml的凝胶计算CPE为33.3%,浓度为2 mg/ml的凝胶为36.4%,浓度为4 mg/ml的凝胶为24.2%。研究表明,大鼠接受CD后,ALP活性显著降低,ACP活性显著升高,心肌梗死(MI)由43.9显著降低至28.9。OHFS凝胶的应用使两种磷酸酶的活性恢复到对照水平,几乎完全使心肌梗死正常化,其中浓度为2 mg/ml的OHFS凝胶最有效。使用含有1 mg/ml和2 mg/ml OHFS的凝胶分别使弹性酶活性降低了6%和12%,而使用含有4 mg/ml OHFS的凝胶则没有导致弹性酶活性降低。从测定大鼠血清中生态失调程度的结果可以看出,CD引起了全身性生态失调的发展。应用OHFS凝胶可显著降低生态失调程度,特别是浓度为1和2 mg/ml的凝胶。口服含OHFS的凝胶可减少牙齿龋齿的发生率,增加牙髓的矿化活性,并减少全身生态失调的程度。OHFS凝胶的最有效浓度为2mg /ml,相当于2.2 mg/kg的剂量。
{"title":"The effect of different doses of octenidine hexafluorosilicate on the development of dental caries in rats","authors":"В. Ю. Анісімов, І. Ю. Борисюк, В. О. Гельмбольдт","doi":"10.32352/0367-3057.6.21.10","DOIUrl":"https://doi.org/10.32352/0367-3057.6.21.10","url":null,"abstract":"At present, ammonium hexafluorosilicate and hexafluorosilicates of organic amonium cations are actively studied as potential anticaries agents, which demonstrate certain advantages over traditional compounds of fluorine. Previously, it was shown that hexafluorosilicates with bactericidal cations of chlorhexidine, polyhexamethyleneguanidine and cetylpyridinium effectively reduce the number and depth of carious lesions of teeth in rats and at the same time significantly improve the biochemical parameters of the pulp of the teeth. \u0000The aim of the work – to study the effect of different doses of octenidine hexafluorosilicate (OHFS) on the incidence of dental caries in rats fed a cariogenic diet (CD). \u0000OHFC preparations were applied to the teeth and gums of rats in the composition of phytogels based on Na-salt of carboxymethylcellulose. In the incisor pulp, the activity of alkaline (ALP) and acidic (ACP) phosphatases, elastase, lysozyme was determined, and the mineralizing index (MI) was calculated. The number and depth of dental caries lesions were calculated and caries prophylactic efficacy (CPE) was calculated. The activity of elastase, catalase, lysozyme and urease was determined in the gums, and the degree of atrophy of the alveolar process was determined. \u0000Determination of dental caries lesions shows that CD does not increase the number of carious lesions, and after the application of gels with OHFS, their number significantly decreases. The most effective was the concentration of the OHFS gel, equal to 2 mg/ml, although the concentration of the OHFS gel 1 mg/ml showed a decrease by 33.3%. The calculated CPE is 33.3% for a gel with 1 mg/ml OHFS, 36.4% for a gel with 2 mg/ml and 24.2% for a gel with 4 mg/ml. It has been shown that in rats receiving CD, the ALP activity significantly decreases and the ACP activity significantly increases, which gives a significant decrease in MI from 43.9 to 28.9. Application of gels with OHFS returns the activity of both phosphatases to the control level and almost completely normalizes MI, and the concentration of OHFS gel of 2 mg/ml turned out to be the most effective. Application of gels with 1 mg/ml and 2 mg/ml OHFS reduced elastase activity by 6% and 12%, respectively, whereas application of a gel with 4 mg/ml OHFS did not result in a decrease in elastase activity. From the results of determining the degree of dysbiosis in the blood serum of rats, it can be seen that CD causes the development of generalized dysbiosis. Application of gels with OHFS significantly reduce the degree of dysbiosis, especially gels with OHFS concentrations of 1 and 2 mg/ml. \u0000Oral application of gels containing OHFS reduces the incidence of caries on the teeth, increases the mineralizing activity of the pulp and reduces the degree of generalized dysbiosis. The most effective concentration of the OHFS gel is 2 mg/ml, which corresponds to a dose of 2.2 mg/kg.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47965455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of anatomical signs of canadian goldenrod herbs, introduced in Ukraine 乌克兰引种的加拿大黄花草本植物解剖特征的调查
Pub Date : 2021-12-20 DOI: 10.32352/0367-3057.6.21.09
Т. М. Гонтова, В. П. Руденко, В. П. Гапоненко, С. А. Козира, С. В. Романова
The monograph «Goldenrod» SPhU 2.0 describes the general morphological and anatomical features of two species – Solidago gigantea Ait and Solidago canadensis L., which are similar. Not all diagnostic signs can be identified in powdered raw materials. It was important to investigate domestic series of сanadian goldenrod and to identify additional diagnostic signs. The aim of the work was to study the series of domestic raw materials of сanadian goldenrod by anatomical features and to determine the totality of individual features of the species to establish the identity of raw materials. The object of the study were samples of сanadian goldenrod grass, which were harvested in August 2020 in the regions of Ukraine. We used an iPhone XR camera, Item PB-2610 V microscope. Important features of the anatomical structure of the raw material of сanadian goldenrod include: the cells of the stem epidermis are parenchymal, ortho-walled, porous, the leaves – sinuous- and ortho-walled. The presence in the pubescence of stems and leaves 3 types of hairs: simple long, 5–8-celled (up to 20), with thickened walls and pointed cell; short, 2–3-celled, with a dormant apical cell; short and headed with a 2–3-celled stalk and a rounded unicellular head; on the surface and edge of the leaves of the involucre – simple short and 3–4-cell hairs, corollas of flowers – multicellular double-row hairs; stem vessels are spiral, ladder, porous and reticulate; schizogenous structures in the stems, leaves and leaves of the involucre; sphenocrystals of inulin in the parenchyma and vessels of the stem, the cells of the corollas of flowers. A series of domestic raw materials of сanadian goldenrod has been studied according to anatomical features, a set of individual features of the species has been determined. The obtained results can be used in plant taxonomy for comparative analysis of morphologically similar species of the genus Zolotushnik, as well as to supplement the section «Identification B» of the monograph SPhU 2.0 «Zolotushnik».
专著《Goldenrod》SPhU 2.0描述了两个物种的一般形态和解剖特征——巨型一枝黄花和加拿大一枝黄花,这两个物种是相似的。并不是所有的诊断标志都能在粉状原料中识别出来。重要的是调查国内的一枝黄花系列,并确定其他诊断迹象。这项工作的目的是通过解剖特征研究一系列国产一枝黄花原料,并确定该物种个体特征的整体性,以确定原料的身份。该研究的对象是2020年8月在乌克兰地区收获的一枝黄花草样本。我们使用了iPhone XR相机,项目PB-2610 V显微镜。加拿大一枝黄花原料解剖结构的重要特征包括:茎表皮细胞是实质的、直壁的、多孔的,叶是弯曲的和直壁的。茎和叶的短柔毛中存在3种类型的毛:单长,5-8细胞(可达20),壁增厚,细胞尖;短,2-3细胞,具休眠顶端细胞;短和头状花序,有2-3细胞的茎和圆形的单细胞头状花序;在总苞的叶的表面和边缘上-简单的短毛和3-4细胞的毛,花的花冠-多细胞的双排毛;茎管呈螺旋状、阶梯状、多孔和网状;总苞的茎、叶和叶中的裂生结构;菊粉的球形晶体在茎的薄壁组织和血管中,茎是花的花冠的细胞。根据云南一枝黄花的解剖特征,对国产一系列原料进行了研究,确定了该品种的一系列个体特征。所获得的结果可用于植物分类学,对Zolotushnik属形态相似物种进行比较分析,并补充专著SPhU 2.0《Zolotushik》的“鉴定B”部分。
{"title":"Investigation of anatomical signs of canadian goldenrod herbs, introduced in Ukraine","authors":"Т. М. Гонтова, В. П. Руденко, В. П. Гапоненко, С. А. Козира, С. В. Романова","doi":"10.32352/0367-3057.6.21.09","DOIUrl":"https://doi.org/10.32352/0367-3057.6.21.09","url":null,"abstract":"The monograph «Goldenrod» SPhU 2.0 describes the general morphological and anatomical features of two species – Solidago gigantea Ait and Solidago canadensis L., which are similar. Not all diagnostic signs can be identified in powdered raw materials. It was important to investigate domestic series of сanadian goldenrod and to identify additional diagnostic signs. \u0000The aim of the work was to study the series of domestic raw materials of сanadian goldenrod by anatomical features and to determine the totality of individual features of the species to establish the identity of raw materials. \u0000The object of the study were samples of сanadian goldenrod grass, which were harvested in August 2020 in the regions of Ukraine. We used an iPhone XR camera, Item PB-2610 V microscope. \u0000Important features of the anatomical structure of the raw material of сanadian goldenrod include: the cells of the stem epidermis are parenchymal, ortho-walled, porous, the leaves – sinuous- and ortho-walled. The presence in the pubescence of stems and leaves 3 types of hairs: simple long, 5–8-celled (up to 20), with thickened walls and pointed cell; short, 2–3-celled, with a dormant apical cell; short and headed with a 2–3-celled stalk and a rounded unicellular head; on the surface and edge of the leaves of the involucre – simple short and 3–4-cell hairs, corollas of flowers – multicellular double-row hairs; stem vessels are spiral, ladder, porous and reticulate; schizogenous structures in the stems, leaves and leaves of the involucre; sphenocrystals of inulin in the parenchyma and vessels of the stem, the cells of the corollas of flowers. \u0000A series of domestic raw materials of сanadian goldenrod has been studied according to anatomical features, a set of individual features of the species has been determined. The obtained results can be used in plant taxonomy for comparative analysis of morphologically similar species of the genus Zolotushnik, as well as to supplement the section «Identification B» of the monograph SPhU 2.0 «Zolotushnik».","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48181642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Farmatsevtichnii zhurnal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1